Antisense Oligonucleotides for Neurodegeneration

📖 Wiki Page

therapeutic970 wordssynced 2026-04-02

Antisense Oligonucleotides for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotides for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">RNase H-Mediated Degradation</td>
<td>ASO-RNA hybrid recruits RNase H to cleave RNA</td>
</tr>
<tr>
<td class="label">Steric Blockade</td>
<td>Blocks translation initiation or splicing machinery</td>
</tr>
<tr>
<td class="label">RNA Silencing</td>
<td>Uses RNA interference pathways</td>
</tr>
<tr>
<td class="label">Splice Modulation</td>
<td>Corrects aberrant splicing patterns</td>
</tr>
<tr>
<td class="label">Allele-Specific Targeting</td>
<td>Targets mutant allele while sparing wild-type</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[Tau](/proteins/tau) (MAPT)</td>
</tr>
<tr>
<td class="label">ASO-GC</td>
<td>GC (MIR137)</td>
</tr>
<tr>
<td class="label">ASO-α-syn</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ATXN2-ASO</td>
<td>ATXN2</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT02644599</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03

...

Antisense Oligonucleotides for Neurodegenerative Diseases

Introduction

Antisense Oligonucleotides For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA or RNA molecules designed to bind to specific messenger RNA (mRNA) sequences, thereby modulating gene expression. ASOs represent a transformative therapeutic modality for neurodegenerative diseases, enabling targeted reduction of toxic protein aggregates, correction of aberrant splicing, and allele-specific silencing of disease-causing mutations. Several ASOs have now received FDA approval for neurological disorders, with numerous candidates in clinical development for Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [@fda2023]

Molecular Mechanism

ASOs employ several mechanisms to achieve therapeutic effects: [@tabrizi2019]

Key Drug Candidates

Tominersen (RG6042)

Target: [HTT](/genes/htt) mRNA (mutant huntingtin)
Mechanism: Allele-nonspecific ASO reduces both mutant and wild-type HTT
Clinical Status: Phase III (GENERATION-HD1) - development discontinued
Evidence: Reduced CSF mutant [huntingtin](/proteins/huntingtin-protein) in Phase I/II trials

Inotersen (Tegsedi)

Target: TTR (transthyretin) mRNA
Mechanism: Reduces both mutant and wild-type TTR production
FDA Status: FDA-approved for hATTR polyneuropathy
Evidence: 79% reduction in TTR protein; improved neuropathy

Nusinersen (Spinraza)

Target: SMN2 mRNA (splicing correction)
Mechanism: Promotes inclusion of exon 7, increasing SMN protein
FDA Status: FDA-approved for spinal muscular atrophy
Evidence: Significant improvement in motor function

Tofersen (Qalsody)

Target: SOD1 mRNA
Mechanism: Reduces mutant SOD1 protein production
FDA Status: FDA-approved for SOD1-ALS (2023)
Evidence: Reduced CSF SOD1, slowed clinical decline

ASOs in Development

Disease-Specific Applications

Huntington's Disease

Tominersen (RG6042): Reduced mHTT by ~40% in CSF
GENERATION-HD1 trial enrolled ~800 patients
Development discontinued but ASO approach validated
Next-generation ASOs with improved delivery in development

Amyotrophic Lateral Sclerosis

Tofersen (Qalsody): First FDA-approved ASO for ALS (SOD1)
Targeting C9orf72, ATXN2, FUS in development
Combination with small molecules in trials

Alzheimer's Disease

BIIB080 (IONIS-MAPTRx): Anti-[tau](/proteins/tau) ASO
Phase I/II showed dose-dependent reduction in CSF tau
Prevents spread of tau pathology
[Aβ](/proteins/amyloid-beta)-targeting ASOs in preclinical development

Parkinson's Disease

ASOs targeting SNCA (α-synuclein) in development
GBA1 gene modulation to enhance glucocerebrosidase
LRRK2-targeting ASOs in preclinical stages

Spinal Muscular Atrophy

Nusinersen (Spinraza): Landmark FDA approval 2016
Risdiplam (Evrysdi): Small molecule splice modifier
Onasemnogene abeparvovec (Zolgensma): Gene therapy

Clinical Trials

Delivery Challenges and Solutions

Blood-Brain Barrier Penetration

ASOs require intrathecal (lumbar puncture) delivery
Conjugation to receptor ligands (e.g., transferrin receptor)
Novel formulations (lipid nanoparticles, exosomes)

Safety Considerations

Off-target effects monitoring required
Spinal muscular atrophy patients require careful monitoring
Dose-dependent liver enzyme elevation possible

Research Directions

Current research focuses on:

Brain-penetrant ASOs for intravenous administration
Allele-specific ASOs for dominant-negative mutations
Combination approaches with gene therapy
Biomarker development for patient selection
Repeat-dosing protocols for sustained benefit

External Links

[FDA Approval Summary - Tofersen](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-qalsody-tofersen-sod1-als)
[ClinicalTrials.gov - ASO Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=antisense+oligonucleotide)
[Ionis Pharmaceuticals Pipeline](https://www.ionispharma.com/pipeline/)

External Links

[PubMed - PGC-1 Alpha Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PGC-1alpha+neurodegeneration)
[NIH - Mitochondrial Biogenesis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/)
[Nature - PGC-1 Alpha and Parkinson's](https://www.nature.com/articles/ncomms3033)
[Cell - Mitochondrial Dynamics](https://www.sciencedirect.com/science/article/pii/S1550413115000537)
[Alzheimer's Research - Mitochondria](https://www.alzheimersresearchuk.org/dementia-topics/mitochondria/)

Background

The study of Antisense Oligonucleotides For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Bennett CF, et al, Antisense oligonucleotide therapeutics for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36653987/)

Unknown, FDA. Qalsody (tofersen) injection approval letter. 2023 (2023)

[Tabrizi SJ, et al, Targeting huntingtin protein in Huntington's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31397647/)

[Miller T, et al, Phase 1-2 trial of tofersen for SOD1 ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32640130/)

[Mercuri E, et al, Nusinersen in spinal muscular atrophy (2018)](https://pubmed.ncbi.nlm.nih.gov/29747944/)

[Mummery CJ, et al, BIIB080 (IONIS-MAPTRx) in mild Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36534356/)

[Hu J, et al, Allele-specific silencing of mutant huntingtin (2020)](https://pubmed.ncbi.nlm.nih.gov/32632293/)

[Kordas G, et al, Antisense oligonucleotides for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35716074/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Antisense Oligonucleotides for Neurodegeneration

Antisense Oligonucleotides for Neurodegenerative Diseases

Antisense Oligonucleotides for Neurodegenerative Diseases

Introduction

Overview

Molecular Mechanism

Key Drug Candidates

Tominersen (RG6042)

Inotersen (Tegsedi)

Nusinersen (Spinraza)

Tofersen (Qalsody)

ASOs in Development

Disease-Specific Applications

Huntington's Disease

Amyotrophic Lateral Sclerosis

Alzheimer's Disease

Parkinson's Disease

Spinal Muscular Atrophy

Clinical Trials

Delivery Challenges and Solutions

Blood-Brain Barrier Penetration

Safety Considerations

Research Directions

See Also

External Links

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses